Jijun Yuan

279 Wenjing Rd
Minhang, 200245, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Journal: Hematological oncology

Published: November 25, 2021

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Journal: Frontiers in oncology

Published: June 16, 2021

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.

Journal: Frontiers in immunology

Published: June 04, 2021

Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.

Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.

Journal: OncoTargets and therapy

Published: August 15, 2020

Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.

Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.

Journal: Bioorganic & medicinal chemistry

Published: October 25, 2017

WITHDRAWN: Discovery of SHR1977: A highly potent and selective ROMK inhibitor.

WITHDRAWN: Discovery of SHR1977: A highly potent and selective ROMK inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: April 10, 2016

Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model.

Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model.

Journal: Bioorganic & medicinal chemistry letters

Published: September 16, 2015

Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.

Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 13, 2014

Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.

Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.

Journal: Bioorganic & medicinal chemistry letters

Published: September 04, 2013

Discovery of novel orally bioavailable GPR40 agonists.

Discovery of novel orally bioavailable GPR40 agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: December 29, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026